Life Science Investing Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Life Science Investing Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Placement to Institutional and Sophisticated Investors, Appointment of Joint Broker,Issue of Equity & TVR